Hengrui Pharma targets obesity drug launch after test success
The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trials Key Takeaways: Participants receiving…
Innogen Pharma jostles for a slice of the weight-loss market
The developer of diabetes and anti-obesity drugs has applied for a Hong Kong IPO as it prepares for battle in a crowded arena Key Takeaways: Innogen is expected to launch…
AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Medtide launches IPO to bulk up its weight-loss business
3880.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
- RNA drug developer Ribo Life targets fresh funding channel
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
- Will Trump’s drug order put the brakes on China’s overseas pharma drive?
-
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
1276.HK 600276.SHG
